Carl Michael Gay

DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab

This study shows DLL3 expression level predicts response and long-term survival in SCLC patients treated with tarlatamab.

YAP1 defines an emergent, plastic population of relapsed small cell lung cancer

This study identifies YAP1-positive cells in relapsed SCLC that exhibit drug tolerance and transition from SCLC to LCNEC-like features, losing some targets but gaining others.

CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level

This study uses CyTOF to profile circulating tumor cells in SCLC patients, identifying subtype-specific markers and treatment response correlations.

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer

This study identifies three distinct DDR phenotypes in SCLC associated with chemotherapy response and tumor evolution.

Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on Survival

This study examines genomic and TCR repertoire heterogeneity in SCLC, finding that lower TCR heterogeneity and mutational burden correlate with better survival.